Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vasopressin and Steroids in addition to Adrenaline in Cardiac Arrest (VAST-A)
2022-500137-89-00Phase 3Terminated
- Sponsor
- TioHundra
- Start
- Mar 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of vasopressin, methylprednisolone sodium succinate, hydrocortisone sodium succinate and epinephrine in cardiac arrest (SCA) (2 arms), sponsored by TioHundra. Primary endpoint: Survival at 30 days. Started Mar 2022; status: terminated.
02
Drugs
vasopressinmethylprednisolone sodium succinatehydrocortisone sodium succinateepinephrine
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on 2022-500137-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500137-89-00.